Document is current

Article History

Received: 1 August 2019

Accepted: 17 October 2019

First Online: 29 October 2019

Ethics approval and consent to participate

: The OTRLASV study is registered on ClinicalTrials.gov (Identifier: NCT02429986). The protocol complied with the Declaration of Helsinki and was reviewed and approved by an independent ethics committee (<i>Comité de Protection des Personnes “Sud Méditérannée III”</i>; reference number 2014.11.04).

: Not applicable.

: Dr. Dany Jaffuel has performed lecturing at sponsored meetings for the following companies in the last 5 years: Apard, Bastide, Loewenstein Medical, Philips, SEFAM. He has sat on advisory boards for the following companies in the last 5 years: Lowenstein Medical, SEFAM. He has received sponsorship support to attend academic meetings in the last 5 years from Lowenstein Medical, Resmed, Philips and SEFAM.- Dr. Alain Palot has performed lecturing at sponsored meetings for the following companies in the last 5 years: ARARD, Resmed, Philips. He has sat on advisory boards for the following company in the last 5 years: Resmed- Dr. Claudio Rabec has performed lecturing at sponsored meetings and/or participated in boards for the following companies in the last 5 years: Resmed, Philips, Lowenstein, Air Liquide Medical SystemsAB, CMS, CP, EN, JPM, NM, MG, SR report no conflicts of interest in relation to the present work.